2cureX continues its IP expansion by securing a patent on Its IndiTreat test in Hong Kong
2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce the granting of a Hong Kong patent (HK1237870) on its key product, IndiTreat®. As previously communicated, 2cureX was granted a European patent (EP3164709) in August 2018 and a Notice of Allowance (15/321,888) in the US in March 2019. The Hong Kong patent will be in force until July 2035.
The expansion of the IndiTreat® patent portfolio is important with regard to establishing future commercial partnerships. A strong protection of IndiTreat® also strengthens the ongoing launch activities and provides a sustained competitive advantage. Patent protection in Hong Kong opens an interesting gateway to the Asian market.
IndiTreat® provides a novel functional test that supports the existing diagnostic processes for clinicians to individualize cancer treatment. The technology identifies the drug treatment to which the individual patient is sensitive and as important to which it is resistant.
“The clinical predictability of the IndiTreat® test is constantly growing. To ensure a successful commercialization of IndiTreat® it is therefore very comforting to see that 2cureX’s patent protection is being broadened out to new attractive markets”, says Ole Thastrup, Chief Executive Officer and he continues; “I am thankful to our highly innovative researchers, who in direct interaction with clinicians have established a strong and competitive platform for designing efficacious cancer treatments”.
To strengthen the commercialization, 2cureX is running eight clinical programs, which continuously provide data that improves the test´s ability to identify the most effective medical treatment for each cancer patient.
For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 22 11 53 99
www.2curex.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Email: ca@skmg.se
Phone: +46 11 32 30 732
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 15th, 2019.
About 2cureX
2cureX has developed the IndiTreat® (Individual Treatment Design) test. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour and identifies the approved cancer treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient will be provided the selected treatment.
IndiTreat® is being clinically validated in eight clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is presently being introduced into the European market through an Early Access Program.
The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).
Tags: